查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2132974

脂質市場報告：趨勢、預測和競爭分析（至2035年）

Lipid Market Report: Trends, Forecast and Competitive Analysis to 2035
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

脂質市場

全球脂質市場前景廣闊，營養補充品、食品飲料、飼料和醫藥市場均蘊藏著巨大的發展機會。預計全球脂質市場規模將從2027年的160億美元成長至2035年的390億美元，2027年至2035年的複合年成長率（CAGR）為9.5%。推動該市場成長的關鍵因素包括：機能性食品配料需求的不斷成長、脂質在營養補充劑中應用日益廣泛以及植物來源的普及。

  • 根據 Lucintel 的預測，按產品類型分類，在對必需脂肪酸補充劑的需求不斷成長的推動下，omega-3 和 omega-6 預計將在整個預測期內保持最大的細分市場。
  • 從應用領域來看，由於 omega 脂肪酸在製藥領域的應用日益廣泛，因此預期製藥業在預測期內將呈現最高的成長率。
  • 從區域來看，在預測期內，歐洲預計將保持最大區域的地位，這主要得益於強勁的營養保健品市場和不斷增強的健康意識。

脂質市場的新趨勢

分析師預測，脂質奈米顆粒（LNP）技術領域未來幾年將快速發展，其應用範圍將超越最初的mRNA疫苗。根據Lucintel的一份報告，遞送平台的創新和應用領域的多元化發展將使行業領導者與一次性疫苗供應商區分開來。

  • LNP技術的應用範圍超越疫苗：除了最初的mRNA疫苗應用外，脂質奈米顆粒技術目前正被應用於腫瘤學、再生醫學和神經病學等領域。鑑於基於LNP的療法在治療罕見遺傳疾病和慢性病方面的研究不斷深入，這項技術將在感染疾病以外的市場領域持續帶來機會。
  • 離子化脂質的工程改進：目前正在進行研究，旨在開發新一代脂質，以提高其生物分解性、核內體逃脫能力和蛋白質表現量。近期研究已實現了比第一代脂質高3至5倍的蛋白質表現量。這項研究將徹底改變mRNA療法在多種疾病和病症中的應用。
  • LNP靶向技術：為了消除全身性脫靶效應，研究人員正在開發能夠將脂質奈米顆粒與特定細胞結合的細胞靶向配體。一種針對肝臟的脂質奈米顆粒遞送系統在臨床前模型中已展現出90%的療效。
  • 外包給合約研發生產機構 (CDMO)：隨著脂質奈米顆粒 (LNP) 生產的擴展，許多製藥公司正在將這項服務外包，使得 LNP 合約研發生產機構 (CDMO) 成為首選。瓦克製藥與 CordenPharma 於 2024 年建立的合作關係便是這一趨勢的典型例證。生物製藥公司正專注於其核心能力——療法研發，而複雜的生產製造需要大量資金投入，因此外包將繼續變得越來越普遍。
  • 人工智慧驅動的製劑設計：研究人員正在將人工智慧和運算建模相結合來設計奈米顆粒，從而簡化開發流程並推動精準遞送機制的發展。隨著計算工具的普及和產業對傳統製劑方法依賴性的降低，這種融合將進一步縮短開發週期。

脂質奈米顆粒正逐漸成為多種藥物製劑（不僅限於疫苗）的主要遞送系統。利用人工智慧設計靶向精度更高的系統的公司，將超越那些使用第一代製劑系統的公司。

脂質市場近期趨勢

從2024年到2026年，隨著製藥公司迅速擴大其內部和外包生產能力以滿足日益成長的RNA治療藥物需求，脂質奈米顆粒市場蓬勃發展。據Lucintel稱，國內生產能力正在重塑競爭格局，其規模堪比技術合作。

  • 重大國內生產投資：2025年11月，Moderna宣布投資超過1.4億美元，在位於麻薩諸塞州諾伍德的工廠增設一條mRNA生產生產線。這項投資將增強Moderna的國內生產能力，並降低其對契約製造組織（CMO）在核心生產方面的依賴。
  • 合作關係：瓦克公司與CordenPharma公司於2024年就脂質奈米顆粒製劑達成合作協議。兩家公司旨在共同開發脂質奈米顆粒的生產能力，以滿足市場需求。此類合作關係為成熟的化學和製藥公司提供了合作開發脂質奈米顆粒製劑的機會，而非完全獨立研發。
  • 市場准入：總部位於亞太地區的Aurora Biosynthetics公司於2024年9月開始運營，提供質體DNA、mRNA和脂質奈米顆粒的端到端GMP生產服務。這標誌著亞太地區正從RNA療法的研究階段邁向實際的商業化生產階段。
  • 生產支持：美國生物醫學高級研究與發展局（BARDA）對贏創的持續政府支持，顯示美國政府致力於保障RNA療法的生產能力。這種程度的政府資助表明，脂質奈米顆粒的生產能力已從單純的商業性活動轉變為國家戰略基礎設施。
  • 擴大供應合約：VAV生命科學公司已與一家合約研發生產機構（CDMO）簽署契約，為其供應疫苗生產所需的奈米顆粒。這是該領域越來越多的公司正式簽署脂質奈米顆粒供應合約的最新例證。隨著業界專注於疫苗和治療藥物的生產，確保脂質奈米顆粒的供應顯然已成為重中之重。業內其他公司也同樣認知到這一點的重要性。

當業內其他公司專注於確保LNP供應等關鍵優先事項時，它們也在積極推動一些最終將塑造產業格局的舉措，包括國內生產和企業合作。正如Moderna和WACKER-CordenPharma所做的那樣，將國內生產能力與合約服務相結合，將使它們能夠在未來十年內保持並鞏固其在行業中的領先地位。

目錄

第1章執行摘要

第2章 市場概覽

  • 背景與分類
  • 供應鏈

第3章 市場趨勢與預測分析

  • 宏觀經濟趨勢與預測
  • 產業促進因素與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

第4章 全球脂質市場：依產品類型分類

  • 吸引力分析：依產品類型
  • 歐米伽-3 和歐米伽-6
  • 中鏈三酸甘油酯
  • 磷脂
  • 其他

第5章：全球脂質市場：依來源分類

  • 吸引力分析：按來源
  • 植物來源
  • 海洋來源
  • 動物源性
  • 合成產品

第6章：全球脂質市場：依形態分類

  • 吸引力分析：按形式
  • 液體
  • 粉末
  • 其他

第7章 全球脂質市場：依應用領域分類

  • 吸引力分析：依目的
  • 營養補充品
  • 食品/飲料
  • 動物飼料
  • 製藥
  • 其他

第8章 區域分析

第9章：北美脂質市場

  • 北美脂質市場：依產品類型分類
  • 北美脂質市場：按應用領域分類
  • 美國脂質市場
  • 加拿大脂質市場
  • 墨西哥脂質市場

第10章：歐洲脂質市場

  • 歐洲脂質市場：依產品類型分類
  • 歐洲脂質市場：依應用領域分類
  • 德國脂質市場
  • 法國脂質市場
  • 義大利脂質市場
  • 西班牙脂質市場
  • 英國脂質市場

第11章：亞太地區的脂質市場

  • 亞太地區脂質市場：依產品類型分類
  • 亞太地區脂質市場：依應用領域分類
  • 中國脂質市場
  • 印度脂質市場
  • 日本脂質市場
  • 韓國的脂質市場
  • 印尼脂質市場

第12章：世界其他地區的脂質市場

  • 其他地區的脂質市場：依產品類型分類
  • 其他地區的脂質市場：依應用領域分類
  • 中東脂質市場
  • 南美洲脂質市場
  • 非洲脂質市場

第13章 競爭分析

  • 產品系列分析
  • 業務整合
  • 波特五力分析
  • 市佔率分析

第14章 機會與策略分析

  • 價值鏈分析
  • 成長機會分析
  • 新趨勢：全球脂質市場
  • 戰略分析

第15章：價值鏈關鍵企業的企業概況

  • 競爭分析概述
  • BASF SE
  • DSM-Firmenich
  • Croda International Plc
  • Solutex GC, SL
  • Clover Corporation Limited
  • Kerry Group Plc
  • Evonik Industries AG
  • Lonza Group
  • Cabio Biotech（Wuhan）Co., Ltd.
  • Stepan Company

第16章附錄

Lipid Market

The future of the global lipid market looks promising with opportunities in the dietary supplement, food & beverage, animal feed, and pharmaceutical markets. The global lipid market is expected to reach an estimated $39 billion by 2035 from $16 billion in 2027 with a CAGR of 9.5% from 2027 to 2035. The major drivers for this market are the increasing demand for functional food ingredients, the rising use of lipids in nutraceuticals, and the growing adoption of plant based oils.

  • Lucintel forecasts that, within the product type category, omega-3 & omega-6 will remain the largest segment over the forecast period due to the growing demand for essential fatty acid nutritional supplements.
  • Within the application category, pharmaceutical is expected to witness the highest growth over the forecast period due to increasing pharmaceutical applications of omega fatty acids.
  • In terms of regions, Europe will remain the largest region over the forecast period due to the strong nutraceutical market and rising health awareness.

Emerging Trends in Lipid Market

Designers predict rapid growth of the lipid nanoparticle (LNP) technology sector beyond the bounds of its original use case of mRNA-based vaccines over the next few years. According to the Lucintel report, delivery platform innovation and widening application diversity will differentiate industry leaders from single-use vaccine suppliers in the future.

  • LNP Technology Going Beyond Vaccines: Beyond its original use case, mRNA vaccines, lipid nanoparticle technologies are being researched for oncology, regenerative medicine, and neurology. Given the expanding research of LNP-delivered therapies for rare genetic disorders and chronic disease treatment, this technology will continue to bring opportunities to market segments beyond infectious diseases.
  • Ionizable Lipid Engineering: Research is underway to develop the next generation of lipids to improve biodegradability, endosomal escape, and protein expression levels. Recent studies have achieved protein expression levels 3-5 times greater than first generation lipids. This research will transform mRNA therapies for a wide range of disorders and diseases.
  • LNP Targeting Technology: With the goal of eliminating systemic off-target effects, cell targeting ligands are being developed to bind lipid nanoparticles to specific cells. A liver-targeted lipid nanoparticle delivery system has been proven to have 90% efficiency in pre-clinical models.
  • CDMO Outsourcing: Growth in lipid nanoparticle (LNP) manufacturing has LNP contract development and manufacturing organizations (CDMOs) being the first choice as most pharmaceutical companies outsource this service. WACKER and CordenPharma's partnership in 2024 is a prime example of this phenomenon. Outsourcing will continue to gain traction because biopharma companies focus on their core competencies of therapy development with complex manufacture- ing requiring high capital expenditures."
  • AI-Assisted Formulation Design: Researchers combine artificial intelligence and computational modeling to design nanoparticles, simplifying the development process and allowing for advancements in precision delivery mechanism. This integration will continue to shorten development timelines as computational tools become available and the industry relies less on traditional formulation methods.

Lipid nanoparticles are becoming a primary delivery system in different drug formulations; they are not just for vaccine formulations. Companies using AI to design systems with targeting precision will outpace those using first generation formulation systems.

Recent Developments in the Lipid Market

The lipid nanoparticle market was bustling from 2024 to 2026 as pharmaceutical companies rushed to produce both in-house and outsourced capacity to meet the demand of the growing RNA therapeutics pipeline. According to Lucintel, domestic manufacturing capacity is now reshaping competition at magnitude comparable to technology partnerships.

  • Major Domestic Manufacturing Investment: Moderna announced in November 2025 a manufacturing investment of more than $140 million to add more mRNA manufacturing stages to its Norwood, Massachusetts facility. This investment increases Moderna's domestic manufacturing readiness and lessens its dependence on contract manufacturing organizations (CMOs) for core manufacturing.
  • Collaboration: WACKER and CordenPharma signed a collaboration agreement on lipid nanoparticle formulation in 2024. Both companies aim to jointly develop the lipid nanoparticle formulation capability to meet the market demand for lipid nanoparticles. Partnership like this allows established chemical and pharmaceutical manufacturing companies the opportunity to develop lipid nanoparticle formulations as a collaborative effort, rather than developing it as a completely standalone effort.
  • Market Entrant: Aurora Biosynthetic, based in Asia Pacific, launched in September 2024 offering end to end GMP manufacturing of plasmid DNA, mRNA, and lipid nanoparticles. This shows that Asia Pacific is moving from the research stage of RNA therapeutics to the real stage of commercial manufacturing.
  • Manufacturing Support: Continued government support for Evonik by BARDA demonstrates government interest to provide manufacturing capability for RNA therapeutics in the U.S. For government funding to be at this level also demonstrates that lipid nanoparticle capacity has moved from a commercial to a strategic national infrastructure.
  • Supply Agreement Expansion: VAV Lifesciences has entered a contract with a CDMO to supply them with the nanoparticles needed for vaccine manufacturing. This is the latest example of a growing number of companies in this sector formalizing lipid nanoparticle supply contracts. The industry has clearly identified securing a supply of LNPs as a priority as this segment of the industry focuses on manufacturing vaccines and therapeutics. The rest of the industry has recognized this as a priority.

While the rest of the industry is focusing on a priority that is as important as securing LNP supply, the rest of the industry is doing things like domestic manufacturing and corporate partnerships that will ultimately shape this industry. Combining domestic capacities and contracted services, like those done by Moderna and WACKER-CordenPharma, will retain and establish powerful positions in the industry for the next decade.

Strategic Growth Opportunities in the Lipid Market

The next few years will create new business opportunities related to lipid nanoparticles (LNPs) extending beyond the use of the technology for mRNA vaccines in oncology, gene therapy, and targeted drug delivery from 2024 to 2026. Per the new Lucintel market study, the highest growth is coming from the suppliers who are able to move beyond the use of vaccines.

  • Oncology and Gene Therapy: The use of LNPs is extending beyond the use of vaccines into the use of cancer treatments and gene editing. As research pipelines are starting to use LNPs to deliver treatments for rare genetic disorders and chronic diseases, new oncology-focused capabilities for formulating LNPs will provide suppliers with opportunities for higher profit potential per treatment compared to what is seen for vaccines.
  • Targeted Delivery: There is a clear business opportunity for precision-targeted therapy for chronic diseases which require multiple treatments. There has been over 90 percent delivery efficiency of liver-targeted LNPs utilized in pre-clinical studies. There is a clear need for new technologies to create organ specific delivery.
  • CDMO Services: The partnership between CordenPharma and WACKER in 2024 outlines how the majority of pharmaceutical companies have opted to outsource their LNP manufacturing instead of developing their own manufacturing capability. Depending on biopharmaceutical companies' RNA therapy manufacturing partnerships, suppliers will gain a stable client relationship through the development of complete CDMO services.
  • Manufacturing Growth in Asia-Pacific: The launch of Aurora Biosynthetic in September 2024 to offer end-to-end GMP manufacturing for mRNA lipid nanoparticles and plasmid DNA in the Asia-Pacific region highlights a clear business opportunity for commercial-scale manufacturing of RNA therapeutics in the region. The first businesses to create a manufacturing infrastructure in the region will have the first-mover advantage before the market matures and the competition increases.
  • AI-Assisted Formulation Development: Using artificial intelligence and computational modeling to design nanoparticles shortens development time. Starting this process will make you stand out from competition that isn't using artificial intelligence.

Diversification of Lipid Nanoparticles is primarily driven by new uses rather than increasing volume of existing formulations. These newly formed partnerships will achieve greater growth potential than companies only involved with legacy, vaccines only, offerings.

Lipid Market Drivers and Challenges

Increased demand for Lipid nanoparticles results from growth in RNA therapeutics. This growth is challenging suppliers with the need for advanced infrastructure to meet the demand. Lucintel projects that the balance between supply and demand will dictate which suppliers expand most profitably during this period.

Key factors

  • Increased Demand for Therapeutics: Rapidly increasing demand for therapeutics for use in mRNA vaccines, cancer therapeutics, and gene therapies drives demand for delivery systems. It is estimated that the global market for Lipid nanoparticles will be approximately $786.4 million by 2024. The expanding demand for RNA therapeutics is creating an even greater need for therapeutics.
  • Enhanced Formulation Technology: Researchers are looking at next generation lipids and expect improved stability and endosomal escape. Several researchers have reported protein expression levels that are a minimum of 3 - 5-fold than the initial lipids. Formulation technology is expected to drive increased therapeutic efficacy and extend the therapeutic window for diseases for which mRNA therapeutics can be used.
  • Domestic Manufacturing: Moderna's investment in November 2025 of over $140 million to expand its lipid nanoparticle manufacturing plant experienced increased domestic manufacturing. This insured active construction and reduced dependence on CMOs for therapeutic lipid nanoparticle utilization.
  • Expansion of CDMO Partnerships: There is an increasing reliance on CMOs demonstrated by the partnership between WACKER and CordenPharma for 2024. This partnership is reflective of the overall increase in partnerships with CMOs as pharmaceutical companies look to outsource to reduce the complexities of manufacturing.
  • Government Funding Support: Public funding, such as BARDA investing in Evonik's lipid nanoparticle manufacturing facility, shows continued government interest in the development of domestic RNA therapeutic manufacturing capacity. The government will likely continue to provide public funding and support the construction of manufacturing infrastructure as states view LNP manufacturing as a strategic capability.

Challenges

  • Manufacturing Scalability Limitations: Producing batches of materials which are consistent and having uniform particles at the commercial scale is technically difficult, and makes it hard to transition production from a clinical to a commercial scale.
  • High Initial Costs: It is difficult to set up lipid nanoparticle manufacturing facilities to meet the Good Manufacturing Practices (GMP) standard, and this tends to generate a lot of financial burden on small biotech companies and local producers in particular.
  • Supply Chain: Raw materials that are ionizable lipids, in particular, are sourced from a few suppliers, and therefore, the manufacturing supply chain is vulnerable to shortages.

High capital and manufacturing scalability will continue to favor well established players with an infrastructure to carry out manufacturing to GMP standards. Focusing on formulation innovation combined with domestic manufacturing will enable these companies to better secure long term supply contracts with biopharma companies in the next few years.

List of Lipid Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies lipid market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the lipid market companies profiled in this report include-

  • BASF SE
  • DSM-Firmenich
  • Croda International Plc
  • Solutex GC, S.L.
  • Clover Corporation Limited
  • Kerry Group Plc
  • Evonik Industries AG
  • Lonza Group
  • Cabio Biotech (Wuhan) Co., Ltd.
  • Stepan Company

Lipid Market by Segment

The study includes a forecast for the global lipid market by product type, source, form, application, and region.

Lipid Market by Product Type [Value ($B) from 2019 to 2035]:

  • Omega-3 & Omega-6
  • Medium-Chain Triglycerides
  • Phospholipids
  • Others

Lipid Market by Source [Value ($B) from 2019 to 2035]:

  • Plant-Based
  • Marine-Based
  • Animal-Based
  • Synthetics

Lipid Market by Form [Value ($B) from 2019 to 2035]:

  • Liquid
  • Powder
  • Others

Lipid Market by Application [Value ($B) from 2019 to 2035]:

  • Dietary Supplements
  • Food & Beverage
  • Animal Feed
  • Pharmaceuticals
  • Others

Lipid Market by Region [Value ($B) from 2019 to 2035]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Lipid Market

Demand for RNA-based therapeutics will drive a surge in interest in the lipid market from 2024 to 2026, greatly increasing the value of the global lipid nanoparticle market from $786.4 million in 2024. As reported by Lucintel, activity in this space will particularly manifest as investments in production capacity and contract development and manufacturing organizations (CDMOs).

  • The United States: Moderna plans to invest more than $140 million in the expansion of its production facility in the Norwalk, Massachusetts, production facility in November 2025. With the new facility, production of different stages of mRNA will occur at a single site. This expansion of production will strengthen U.S. readiness and reduce the need for external lipid nanoparticle manufacturers.
  • China: Chinese biotechnology companies attract investments in lipid nanoparticle manufacturing. These companies are positioned in one of the less expensive production sites along the global supply chain for mRNA and RNA therapeutic manufacturing. This investment will allow China to become a competitive lipid nanoparticle manufacturing site in the Asia-Pacific region.
  • Germany: In 2024, WACKER and CordenPharma will enter a partnership to develop on a scale the production of lipid nanoparticles. This partnership will allow Germany to fulfill the market demand for GMP-compliant lipid nanoparticle production and strengthen the role of Germany in the European lipid nanoparticle CDMO market, valued at $0.08 billion in 2025.
  • India: The rapidly expanding and cost-competitive lipid nanoparticle manufacturing capacity, coupled with government support for local biologics manufacturing and innovation, has resulted in significant investments in Indian biopharma manufacturing. This has the potential to make India one of the fastest growing lipid nanoparticle manufacturing locations in the Asia-Pacific region, along with China.
  • Japan: Japanese research institutions and biotechnology companies continue to advance research and development of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and oncology purposes. Supported by the steady investment in biotech collaboration, Japan continues to lead the lipid nanoparticle market in the region.

Features of the Global Lipid Market

  • Market Size Estimates: lipid market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
  • Segmentation Analysis: lipid market size by various segments, such as by product type, source, form, application, and region in terms of value ($B).
  • Regional Analysis: lipid market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different product types, sources, forms, applications, and regions for the lipid market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the lipid market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the lipid market by product type (omega-3 & omega-6, medium-chain triglycerides, phospholipids, and others), source (plant-based, marine-based, animal-based, and synthetics), form (liquid, powder, and others), application (dietary supplements, food & beverage, animal feed, pharmaceuticals, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 6 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Lipid Market by Product Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Product Type
  • 4.3 Omega-3 & Omega-6 : Trends and Forecast (2019 to 2035)
  • 4.4 Medium-Chain Triglycerides : Trends and Forecast (2019 to 2035)
  • 4.5 Phospholipids : Trends and Forecast (2019 to 2035)
  • 4.6 Others : Trends and Forecast (2019 to 2035)

5. Global Lipid Market by Source

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Source
  • 5.3 Plant-Based : Trends and Forecast (2019 to 2035)
  • 5.4 Marine-Based : Trends and Forecast (2019 to 2035)
  • 5.5 Animal-Based : Trends and Forecast (2019 to 2035)
  • 5.6 Synthetics : Trends and Forecast (2019 to 2035)

6. Global Lipid Market by Form

  • 6.1 Overview
  • 6.2 Attractiveness Analysis by Form
  • 6.3 Liquid : Trends and Forecast (2019 to 2035)
  • 6.4 Powder : Trends and Forecast (2019 to 2035)
  • 6.5 Others : Trends and Forecast (2019 to 2035)

7. Global Lipid Market by Application

  • 7.1 Overview
  • 7.2 Attractiveness Analysis by Application
  • 7.3 Dietary Supplements : Trends and Forecast (2019 to 2035)
  • 7.4 Food & Beverage : Trends and Forecast (2019 to 2035)
  • 7.5 Animal Feed : Trends and Forecast (2019 to 2035)
  • 7.6 Pharmaceuticals : Trends and Forecast (2019 to 2035)
  • 7.7 Others : Trends and Forecast (2019 to 2035)

8. Regional Analysis

  • 8.1 Overview
  • 8.2 Global Lipid Market by Region

9. North American Lipid Market

  • 9.1 Overview
  • 9.2 North American Lipid Market by Product Type
  • 9.3 North American Lipid Market by Application
  • 9.4 The United States Lipid Market
  • 9.5 Canadian Lipid Market
  • 9.6 Mexican Lipid Market

10. European Lipid Market

  • 10.1 Overview
  • 10.2 European Lipid Market by Product Type
  • 10.3 European Lipid Market by Application
  • 10.4 German Lipid Market
  • 10.5 French Lipid Market
  • 10.6 Italian Lipid Market
  • 10.7 Spanish Lipid Market
  • 10.8 The United Kingdom Lipid Market

11. APAC Lipid Market

  • 11.1 Overview
  • 11.2 APAC Lipid Market by Product Type
  • 11.3 APAC Lipid Market by Application
  • 11.4 Chinese Lipid Market
  • 11.5 Indian Lipid Market
  • 11.6 Japanese Lipid Market
  • 11.7 South Korean Lipid Market
  • 11.8 Indonesian Lipid Market

12. ROW Lipid Market

  • 12.1 Overview
  • 12.2 ROW Lipid Market by Product Type
  • 12.3 ROW Lipid Market by Application
  • 12.4 Middle Eastern Lipid Market
  • 12.5 South American Lipid Market
  • 12.6 African Lipid Market

13. Competitor Analysis

  • 13.1 Product Portfolio Analysis
  • 13.2 Operational Integration
  • 13.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 13.4 Market Share Analysis

14. Opportunities & Strategic Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Growth Opportunity Analysis
    • 14.2.1 Growth Opportunity by Product Type
    • 14.2.2 Growth Opportunity by Source
    • 14.2.3 Growth Opportunity by Form
    • 14.2.4 Growth Opportunity by Application
    • 14.2.5 Growth Opportunity by Region
  • 14.3 Emerging Trends in the Global Lipid Market
  • 14.4 Strategic Analysis
    • 14.4.1 New Product Development
    • 14.4.2 Certification and Licensing
    • 14.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

15. Company Profiles of the Leading Players Across the Value Chain

  • 15.1 Competitive Analysis Overview
  • 15.2 BASF SE
    • Company Overview
    • Lipid Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.3 DSM-Firmenich
    • Company Overview
    • Lipid Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.4 Croda International Plc
    • Company Overview
    • Lipid Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.5 Solutex GC, S.L.
    • Company Overview
    • Lipid Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.6 Clover Corporation Limited
    • Company Overview
    • Lipid Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.7 Kerry Group Plc
    • Company Overview
    • Lipid Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.8 Evonik Industries AG
    • Company Overview
    • Lipid Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.9 Lonza Group
    • Company Overview
    • Lipid Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.10 Cabio Biotech (Wuhan) Co., Ltd.
    • Company Overview
    • Lipid Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 15.11 Stepan Company
    • Company Overview
    • Lipid Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

16. Appendix

  • 16.1 List of Figures
  • 16.2 List of Tables
  • 16.3 Research Methodology
  • 16.4 Disclaimer
  • 16.5 Copyright
  • 16.6 Abbreviations and Technical Units
  • 16.7 About Us
  • 16.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Lipid Market
  • Figure 2.1: Usage of Lipid Market
  • Figure 2.2: Classification of the Global Lipid Market
  • Figure 2.3: Supply Chain of the Global Lipid Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 3.19: Driver and Challenges of the Lipid Market
  • Figure 4.1: Global Lipid Market by Product Type in 2019, 2026, and 2035
  • Figure 4.2: Trends of the Global Lipid Market ($B) by Product Type
  • Figure 4.3: Forecast for the Global Lipid Market ($B) by Product Type
  • Figure 4.4: Trends and Forecast for Omega-3 & Omega-6 in the Global Lipid Market (2019-2035)
  • Figure 4.5: Trends and Forecast for Medium-Chain Triglycerides in the Global Lipid Market (2019-2035)
  • Figure 4.6: Trends and Forecast for Phospholipids in the Global Lipid Market (2019-2035)
  • Figure 4.7: Trends and Forecast for Others in the Global Lipid Market (2019-2035)
  • Figure 5.1: Global Lipid Market by Source in 2019, 2026, and 2035
  • Figure 5.2: Trends of the Global Lipid Market ($B) by Source
  • Figure 5.3: Forecast for the Global Lipid Market ($B) by Source
  • Figure 5.4: Trends and Forecast for Plant-Based in the Global Lipid Market (2019-2035)
  • Figure 5.5: Trends and Forecast for Marine-Based in the Global Lipid Market (2019-2035)
  • Figure 5.6: Trends and Forecast for Animal-Based in the Global Lipid Market (2019-2035)
  • Figure 5.7: Trends and Forecast for Synthetics in the Global Lipid Market (2019-2035)
  • Figure 6.1: Global Lipid Market by Form in 2019, 2026, and 2035
  • Figure 6.2: Trends of the Global Lipid Market ($B) by Form
  • Figure 6.3: Forecast for the Global Lipid Market ($B) by Form
  • Figure 6.4: Trends and Forecast for Liquid in the Global Lipid Market (2019-2035)
  • Figure 6.5: Trends and Forecast for Powder in the Global Lipid Market (2019-2035)
  • Figure 6.6: Trends and Forecast for Others in the Global Lipid Market (2019-2035)
  • Figure 7.1: Global Lipid Market by Application in 2019, 2026, and 2035
  • Figure 7.2: Trends of the Global Lipid Market ($B) by Application
  • Figure 7.3: Forecast for the Global Lipid Market ($B) by Application
  • Figure 7.4: Trends and Forecast for Dietary Supplements in the Global Lipid Market (2019-2035)
  • Figure 7.5: Trends and Forecast for Food & Beverage in the Global Lipid Market (2019-2035)
  • Figure 7.6: Trends and Forecast for Animal Feed in the Global Lipid Market (2019-2035)
  • Figure 7.7: Trends and Forecast for Pharmaceuticals in the Global Lipid Market (2019-2035)
  • Figure 7.8: Trends and Forecast for Others in the Global Lipid Market (2019-2035)
  • Figure 8.1: Trends of the Global Lipid Market ($B) by Region (2019-2026)
  • Figure 8.2: Forecast for the Global Lipid Market ($B) by Region (2027-2035)
  • Figure 9.1: Trends and Forecast for the North American Lipid Market (2019-2035)
  • Figure 9.2: North American Lipid Market by Product Type in 2019, 2026, and 2035
  • Figure 9.3: Trends of the North American Lipid Market ($B) by Product Type (2019-2026)
  • Figure 9.4: Forecast for the North American Lipid Market ($B) by Product Type (2027-2035)
  • Figure 9.5: North American Lipid Market by Source in 2019, 2026, and 2035
  • Figure 9.6: Trends of the North American Lipid Market ($B) by Source (2019-2026)
  • Figure 9.7: Forecast for the North American Lipid Market ($B) by Source (2027-2035)
  • Figure 9.8: Trends and Forecast for the United States Lipid Market ($B) (2019-2035)
  • Figure 9.9: Trends and Forecast for the Mexican Lipid Market ($B) (2019-2035)
  • Figure 9.10: Trends and Forecast for the Canadian Lipid Market ($B) (2019-2035)
  • Figure 10.1: Trends and Forecast for the European Lipid Market (2019-2035)
  • Figure 10.2: European Lipid Market by Product Type in 2019, 2026, and 2035
  • Figure 10.3: Trends of the European Lipid Market ($B) by Product Type (2019-2026)
  • Figure 10.4: Forecast for the European Lipid Market ($B) by Product Type (2027-2035)
  • Figure 10.5: European Lipid Market by Source in 2019, 2026, and 2035
  • Figure 10.6: Trends of the European Lipid Market ($B) by Source (2019-2026)
  • Figure 10.7: Forecast for the European Lipid Market ($B) by Source (2027-2035)
  • Figure 10.8: Trends and Forecast for the German Lipid Market ($B) (2019-2035)
  • Figure 10.9: Trends and Forecast for the French Lipid Market ($B) (2019-2035)
  • Figure 10.10: Trends and Forecast for the Spanish Lipid Market ($B) (2019-2035)
  • Figure 10.11: Trends and Forecast for the Italian Lipid Market ($B) (2019-2035)
  • Figure 10.12: Trends and Forecast for the United Kingdom Lipid Market ($B) (2019-2035)
  • Figure 11.1: Trends and Forecast for the APAC Lipid Market (2019-2035)
  • Figure 11.2: APAC Lipid Market by Product Type in 2019, 2026, and 2035
  • Figure 11.3: Trends of the APAC Lipid Market ($B) by Product Type (2019-2026)
  • Figure 11.4: Forecast for the APAC Lipid Market ($B) by Product Type (2027-2035)
  • Figure 11.5: APAC Lipid Market by Source in 2019, 2026, and 2035
  • Figure 11.6: Trends of the APAC Lipid Market ($B) by Source (2019-2026)
  • Figure 11.7: Forecast for the APAC Lipid Market ($B) by Source (2027-2035)
  • Figure 11.8: Trends and Forecast for the Japanese Lipid Market ($B) (2019-2035)
  • Figure 11.9: Trends and Forecast for the Indian Lipid Market ($B) (2019-2035)
  • Figure 11.10: Trends and Forecast for the Chinese Lipid Market ($B) (2019-2035)
  • Figure 11.11: Trends and Forecast for the South Korean Lipid Market ($B) (2019-2035)
  • Figure 11.12: Trends and Forecast for the Indonesian Lipid Market ($B) (2019-2035)
  • Figure 12.1: Trends and Forecast for the ROW Lipid Market (2019-2035)
  • Figure 12.2: ROW Lipid Market by Product Type in 2019, 2026, and 2035
  • Figure 12.3: Trends of the ROW Lipid Market ($B) by Product Type (2019-2026)
  • Figure 12.4: Forecast for the ROW Lipid Market ($B) by Product Type (2027-2035)
  • Figure 12.5: ROW Lipid Market by Source in 2019, 2026, and 2035
  • Figure 12.6: Trends of the ROW Lipid Market ($B) by Source (2019-2026)
  • Figure 12.7: Forecast for the ROW Lipid Market ($B) by Source (2027-2035)
  • Figure 12.8: Trends and Forecast for the Middle Eastern Lipid Market ($B) (2019-2035)
  • Figure 12.9: Trends and Forecast for the South American Lipid Market ($B) (2019-2035)
  • Figure 12.10: Trends and Forecast for the African Lipid Market ($B) (2019-2035)
  • Figure 13.1: Porter's Five Forces Analysis of the Global Lipid Market
  • Figure 13.2: Market Share (%) of Top Players in the Global Lipid Market (2026)
  • Figure 14.1: Growth Opportunities for the Global Lipid Market by Product Type
  • Figure 14.2: Growth Opportunities for the Global Lipid Market by Source
  • Figure 14.3: Growth Opportunities for the Global Lipid Market by Form
  • Figure 14.4: Growth Opportunities for the Global Lipid Market by Application
  • Figure 14.5: Growth Opportunities for the Global Lipid Market by Region
  • Figure 14.6: Emerging Trends in the Global Lipid Market

List of Tables

  • Table 1.1: Growth Rate (%, 2025-2026) and CAGR (%, 2027-2035) of the Lipid Market by Product Type, Source, Form, and Application
  • Table 1.2: Attractiveness Analysis for the Lipid Market by Region
  • Table 1.3: Global Lipid Market Parameters and Attributes
  • Table 3.1: Trends of the Global Lipid Market (2019-2026)
  • Table 3.2: Forecast for the Global Lipid Market (2027-2035)
  • Table 4.1: Attractiveness Analysis for the Global Lipid Market by Product Type
  • Table 4.2: Market Size and CAGR of Various Product Type in the Global Lipid Market (2019-2026)
  • Table 4.3: Market Size and CAGR of Various Product Type in the Global Lipid Market (2027-2035)
  • Table 4.4: Trends of Omega-3 & Omega-6 in the Global Lipid Market (2019-2026)
  • Table 4.5: Forecast for Omega-3 & Omega-6 in the Global Lipid Market (2027-2035)
  • Table 4.6: Trends of Medium-Chain Triglycerides in the Global Lipid Market (2019-2026)
  • Table 4.7: Forecast for Medium-Chain Triglycerides in the Global Lipid Market (2027-2035)
  • Table 4.8: Trends of Phospholipids in the Global Lipid Market (2019-2026)
  • Table 4.9: Forecast for Phospholipids in the Global Lipid Market (2027-2035)
  • Table 4.10: Trends of Others in the Global Lipid Market (2019-2026)
  • Table 4.11: Forecast for Others in the Global Lipid Market (2027-2035)
  • Table 5.1: Attractiveness Analysis for the Global Lipid Market by Source
  • Table 5.2: Market Size and CAGR of Various Source in the Global Lipid Market (2019-2026)
  • Table 5.3: Market Size and CAGR of Various Source in the Global Lipid Market (2027-2035)
  • Table 5.4: Trends of Plant-Based in the Global Lipid Market (2019-2026)
  • Table 5.5: Forecast for Plant-Based in the Global Lipid Market (2027-2035)
  • Table 5.6: Trends of Marine-Based in the Global Lipid Market (2019-2026)
  • Table 5.7: Forecast for Marine-Based in the Global Lipid Market (2027-2035)
  • Table 5.8: Trends of Animal-Based in the Global Lipid Market (2019-2026)
  • Table 5.9: Forecast for Animal-Based in the Global Lipid Market (2027-2035)
  • Table 5.10: Trends of Synthetics in the Global Lipid Market (2019-2026)
  • Table 5.11: Forecast for Synthetics in the Global Lipid Market (2027-2035)
  • Table 6.1: Attractiveness Analysis for the Global Lipid Market by Form
  • Table 6.2: Market Size and CAGR of Various Form in the Global Lipid Market (2019-2026)
  • Table 6.3: Market Size and CAGR of Various Form in the Global Lipid Market (2027-2035)
  • Table 6.4: Trends of Liquid in the Global Lipid Market (2019-2026)
  • Table 6.5: Forecast for Liquid in the Global Lipid Market (2027-2035)
  • Table 6.6: Trends of Powder in the Global Lipid Market (2019-2026)
  • Table 6.7: Forecast for Powder in the Global Lipid Market (2027-2035)
  • Table 6.8: Trends of Others in the Global Lipid Market (2019-2026)
  • Table 6.9: Forecast for Others in the Global Lipid Market (2027-2035)
  • Table 7.1: Attractiveness Analysis for the Global Lipid Market by Application
  • Table 7.2: Market Size and CAGR of Various Application in the Global Lipid Market (2019-2026)
  • Table 7.3: Market Size and CAGR of Various Application in the Global Lipid Market (2027-2035)
  • Table 7.4: Trends of Dietary Supplements in the Global Lipid Market (2019-2026)
  • Table 7.5: Forecast for Dietary Supplements in the Global Lipid Market (2027-2035)
  • Table 7.6: Trends of Food & Beverage in the Global Lipid Market (2019-2026)
  • Table 7.7: Forecast for Food & Beverage in the Global Lipid Market (2027-2035)
  • Table 7.8: Trends of Animal Feed in the Global Lipid Market (2019-2026)
  • Table 7.9: Forecast for Animal Feed in the Global Lipid Market (2027-2035)
  • Table 7.10: Trends of Pharmaceuticals in the Global Lipid Market (2019-2026)
  • Table 7.11: Forecast for Pharmaceuticals in the Global Lipid Market (2027-2035)
  • Table 7.12: Trends of Others in the Global Lipid Market (2019-2026)
  • Table 7.13: Forecast for Others in the Global Lipid Market (2027-2035)
  • Table 8.1: Market Size and CAGR of Various Regions in the Global Lipid Market (2019-2026)
  • Table 8.2: Market Size and CAGR of Various Regions in the Global Lipid Market (2027-2035)
  • Table 9.1: Trends of the North American Lipid Market (2019-2026)
  • Table 9.2: Forecast for the North American Lipid Market (2027-2035)
  • Table 9.3: Market Size and CAGR of Various Product Type in the North American Lipid Market (2019-2026)
  • Table 9.4: Market Size and CAGR of Various Product Type in the North American Lipid Market (2027-2035)
  • Table 9.5: Market Size and CAGR of Various Source in the North American Lipid Market (2019-2026)
  • Table 9.6: Market Size and CAGR of Various Source in the North American Lipid Market (2027-2035)
  • Table 9.7: Trends and Forecast for the United States Lipid Market (2019-2035)
  • Table 9.8: Trends and Forecast for the Mexican Lipid Market (2019-2035)
  • Table 9.9: Trends and Forecast for the Canadian Lipid Market (2019-2035)
  • Table 10.1: Trends of the European Lipid Market (2019-2026)
  • Table 10.2: Forecast for the European Lipid Market (2027-2035)
  • Table 10.3: Market Size and CAGR of Various Product Type in the European Lipid Market (2019-2026)
  • Table 10.4: Market Size and CAGR of Various Product Type in the European Lipid Market (2027-2035)
  • Table 10.5: Market Size and CAGR of Various Source in the European Lipid Market (2019-2026)
  • Table 10.6: Market Size and CAGR of Various Source in the European Lipid Market (2027-2035)
  • Table 10.7: Trends and Forecast for the German Lipid Market (2019-2035)
  • Table 10.8: Trends and Forecast for the French Lipid Market (2019-2035)
  • Table 10.9: Trends and Forecast for the Spanish Lipid Market (2019-2035)
  • Table 10.10: Trends and Forecast for the Italian Lipid Market (2019-2035)
  • Table 10.11: Trends and Forecast for the United Kingdom Lipid Market (2019-2035)
  • Table 11.1: Trends of the APAC Lipid Market (2019-2026)
  • Table 11.2: Forecast for the APAC Lipid Market (2027-2035)
  • Table 11.3: Market Size and CAGR of Various Product Type in the APAC Lipid Market (2019-2026)
  • Table 11.4: Market Size and CAGR of Various Product Type in the APAC Lipid Market (2027-2035)
  • Table 11.5: Market Size and CAGR of Various Source in the APAC Lipid Market (2019-2026)
  • Table 11.6: Market Size and CAGR of Various Source in the APAC Lipid Market (2027-2035)
  • Table 11.7: Trends and Forecast for the Japanese Lipid Market (2019-2035)
  • Table 11.8: Trends and Forecast for the Indian Lipid Market (2019-2035)
  • Table 11.9: Trends and Forecast for the Chinese Lipid Market (2019-2035)
  • Table 11.10: Trends and Forecast for the South Korean Lipid Market (2019-2035)
  • Table 11.11: Trends and Forecast for the Indonesian Lipid Market (2019-2035)
  • Table 12.1: Trends of the ROW Lipid Market (2019-2026)
  • Table 12.2: Forecast for the ROW Lipid Market (2027-2035)
  • Table 12.3: Market Size and CAGR of Various Product Type in the ROW Lipid Market (2019-2026)
  • Table 12.4: Market Size and CAGR of Various Product Type in the ROW Lipid Market (2027-2035)
  • Table 12.5: Market Size and CAGR of Various Source in the ROW Lipid Market (2019-2026)
  • Table 12.6: Market Size and CAGR of Various Source in the ROW Lipid Market (2027-2035)
  • Table 12.7: Trends and Forecast for the Middle Eastern Lipid Market (2019-2035)
  • Table 12.8: Trends and Forecast for the South American Lipid Market (2019-2035)
  • Table 12.9: Trends and Forecast for the African Lipid Market (2019-2035)
  • Table 13.1: Product Mapping of Lipid Suppliers Based on Segments
  • Table 13.2: Operational Integration of Lipid Manufacturers
  • Table 13.3: Rankings of Suppliers Based on Lipid Revenue
  • Table 14.1: New Product Launches by Major Lipid Producers (2019-2026)
  • Table 14.2: Certification Acquired by Major Competitor in the Global Lipid Market